# Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma

> **NCT05275062** · EARLY_PHASE1 · UNKNOWN · sponsor: **Beijing Immunochina Medical Science & Technology Co., Ltd.** · enrollment: 6 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Gastric Cancer
- Esophagogastric Junction Cancer
- Pancreatic Cancer

## Interventions

- **DRUG:** IM92 CAR-T cells

## Key facts

- **NCT ID:** NCT05275062
- **Lead sponsor:** Beijing Immunochina Medical Science & Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-15
- **Primary completion:** 2024-03-01
- **Final completion:** 2024-05-01
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2022-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05275062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05275062, "Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05275062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*